Medigen Biotechnology (Taiwan) Performance
| 3176 Stock | TWD 34.50 0.15 0.44% |
The company secures a Beta (Market Risk) of 0.61, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Medigen Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medigen Biotechnology is expected to be smaller as well. At this point, Medigen Biotechnology has a negative expected return of -0.17%. Please make sure to verify Medigen Biotechnology's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if Medigen Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 2.2 B | |
| Total Cashflows From Investing Activities | -910.5 M |
Medigen |
Medigen Biotechnology Relative Risk vs. Return Landscape
If you would invest 3,865 in Medigen Biotechnology on August 24, 2024 and sell it today you would lose (415.00) from holding Medigen Biotechnology or give up 10.74% of portfolio value over 90 days. Medigen Biotechnology is generating negative expected returns and assumes 1.7455% volatility on return distribution over the 90 days horizon. Simply put, 15% of stocks are less volatile than Medigen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medigen Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medigen Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medigen Biotechnology, and traders can use it to determine the average amount a Medigen Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0949
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 3176 |
Estimated Market Risk
| 1.75 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medigen Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medigen Biotechnology by adding Medigen Biotechnology to a well-diversified portfolio.
Medigen Biotechnology Fundamentals Growth
Medigen Stock prices reflect investors' perceptions of the future prospects and financial health of Medigen Biotechnology, and Medigen Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medigen Stock performance.
| Return On Equity | -0.0022 | |||
| Return On Asset | 0.0036 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 2.9 B | |||
| Shares Outstanding | 139.45 M | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 1.66 X | |||
| Revenue | 3.92 B | |||
| EBITDA | 1.35 B | |||
| Total Debt | 470.77 M | |||
| Book Value Per Share | 18.24 X | |||
| Cash Flow From Operations | 518.12 M | |||
| Earnings Per Share | (0.51) X | |||
| Total Asset | 8.2 B | |||
About Medigen Biotechnology Performance
Evaluating Medigen Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medigen Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medigen Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Medigen Biotechnology performance evaluation
Checking the ongoing alerts about Medigen Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medigen Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medigen Biotechnology generated a negative expected return over the last 90 days | |
| The company reported the revenue of 3.92 B. Net Loss for the year was (52.61 M) with profit before overhead, payroll, taxes, and interest of 2.55 B. | |
| About 25.0% of the company shares are owned by insiders or employees |
- Analyzing Medigen Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medigen Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Medigen Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medigen Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medigen Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medigen Biotechnology's stock. These opinions can provide insight into Medigen Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medigen Stock Analysis
When running Medigen Biotechnology's price analysis, check to measure Medigen Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Biotechnology is operating at the current time. Most of Medigen Biotechnology's value examination focuses on studying past and present price action to predict the probability of Medigen Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Biotechnology's price. Additionally, you may evaluate how the addition of Medigen Biotechnology to your portfolios can decrease your overall portfolio volatility.